^
    Back
    Association details:
    Biomarker:MET expression
    Cancer:Solid Tumor
    Drug:BYON3521 (DNA replication inhibitor, c-MET-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

    Excerpt:
    ...- Part 2: Tumour c-MET membrane expression by immunohistochemistry (IHC score ≥ 2+) as determined by the central laboratory on most recent available/obtained tumour material from a site...
    Trial ID:
    BYON3521.001
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Mol Cancer Ther
    Title:

    Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate

    Published date:
    06/01/2023
    Excerpt:
    BYON3521 showed good potency and full efficacy in MET-amplified and high MET–expressing cancer cell lines; in moderate and low MET–expressing cancer cell lines good potencies and partial efficacy were observed. In mouse xenograft models, BYON3521 showed significant antitumor activity upon single-dose administration in multiple non-MET–amplified tumor types with low, moderate, and high MET expression, including complete tumor remissions in models with moderate MET expression....The performance of BYON3521 in vivo was evaluated in the gastric adenocarcinoma MKN-45 cell line–derived xenograft model (CDX; MET amplified), a mouse clinical trial (MCT) in patient-derived xenograft (PDX) models...
    DOI:
    https://doi.org/10.1158/1535-7163.MCT-22-0596